Christopher Dvorak

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Christopher Dvorak sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

Christopher Dvorak: 1 sponsored US clinical trial, 1 recruiting.

Christopher Dvorak sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Graft-Versus-Host Disease, with 1 trials.

Mid-pack sponsor footprint

Christopher Dvorak is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING NA

A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

NCT04337515

Therapeutic Areas

Graft-Versus-Host Disease 1
Graft Vs Host Disease 1

What is open in the Christopher Dvorak pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Graft-Versus-Host Disease (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Christopher Dvorak: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Christopher Dvorak sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Christopher Dvorak1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Christopher Dvorak sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Christopher Dvorak sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Christopher Dvorak page

1 registered trials is a research-attention snapshot, not an endorsement of Christopher Dvorak or any single study.

  • 1 of Christopher Dvorak's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Graft-Versus-Host Disease is the condition Christopher Dvorak studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Graft-Versus-Host Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Christopher Dvorak pipeline card: 1 registered trials from official public datasets.Report a data error.